Medicare begins 2026 pilot letting beneficiaries spend up to $500 yearly on hemp-derived CBD, sparking debate over safety and regulation.

Starting in April 2026, Medicare will launch a pilot program allowing beneficiaries to use up to $500 annually on hemp-derived CBD products, sparking debate over public health risks and regulatory inconsistencies. While proponents highlight potential benefits for chronic pain, sleep, and anxiety, critics warn the initiative may expose older adults to unproven, poorly regulated products lacking standardized potency, purity, or clinical validation. The program contrasts with strict FDA requirements for pharmaceuticals, raising concerns about undermining scientific standards and discouraging proper drug development. Although the pilot could generate real-world data, inconsistent product quality may limit its reliability. The outcome may shape whether cannabinoids are treated as medicine or unregulated wellness items.